- Cytolon and T-Cell Europe agree on cooperation
- Cytolon initiates global development of DIT - Distributed-Inventory-TechnologyTM
- Cytolon joins Personalized Medicine Coalition
- Cytolon successful with second financing round
- Cytolon gains Patent for CordMatch® in Australia
- Cytolon and DKMS Cord Blood Bank announce collaboration for CordMatch’s Beta-Testing Phase
- Timm Jessen Joins Cytolon’s Supervisory Board
- Cytolon Partners with iSoft for New Life Science Research Tool
- Michaela Servas joins Cytolon´s Supervisory Board
- Cytolon Co-Founder Prof. Dr. Joachim Dudenhausen receives Order of Merit
- CordMatch® goes live
- Cytolon Partners with CSC to Develop CordMatch®
- Cytolon Closes Its First Round of Financing
- Wolfgang Jünger Joins Cytolon's Supervisory Board
- Katherina Reiche, MdB, Steps Down From Cytolon's Supervisory Board to Become a Member of the Federal Government of Germany
- Cytolon Receives the "MOST PROMISING COMPANY LAUNCHED IN 2009 AWARD"
- Cytolon Announces Cooperative Agreement with ARCWAY
- Start-up Financing Begins
- The Launching of Cytolon AG
Michaela Servas joins Cytolon´s Supervisory Board
Berlin, November 3rd 2010 - Cytolon AG announced today that Michaela Servas has accepted an appointment to the company´s Supervisory Board. Michaela Servas is an entrepreneur from the Healthcare sector who brings to Cytolon all her international experience with finances and marketing organization.
Thomas Klein, Cytolon’s Founder and Chief Executive Officer, stated “Ms. Servas is an entrepreneur of unmatched caliber with great experience in the Healthcare field. We are extremely pleased that she accepted to be part of Cytolon´s Supervisory Board”.
Michaela Servas stated “Cytolon has an exciting business model in an area that will prove of great relevance to many people. I am thrilled to work in a company that is globally oriented from day one”.
Biographies of each member of the Supervisory Board are available on our website at www.cytolon.com, the content of which is not part of this press release.
About Cytolon AG:
Cytolon AG is a private Company based in Berlin, Germany that has developed a proprietary, patent-pending, global, internet-based cord blood brokering platform termed CordMatch®. This platform is positioned to profit from the crossroad of the personal data and cellular therapeutic markets of regenerative medicine. Cytolon's mission is to be the world's first trusted source for getting the correct, best-matched cord blood unit (CBU) to the patient that needs it in a timely manner. An accurate cord blood matching platform is imperative as a CBU must accurately match the histocompatibility antigens and the genetic needs of the patient. Cytolon provides solutions and services for today and the future so world-wide transplant centers can talk efficiently and effectively to world-wide cord blood banks, registries, industry partners and service providers. Cytolon focuses on penetrating immediate and emerging markets in the cord blood and stem cell area. For more information, please visit the company's Web site at www.cytolon.com.
Contact:
Nina Hofle - PR
Cytolon AG
Am Karlsbad 15
10785 Berlin - Germany
phone: +49 (0) 30 2639 2880
fax: +49 (0) 30 2639 28820
e-mail: info@cytolon.com
web: www.cytolon.com